Chelator-induced enhancement of 67Ga tumour imaging: comparison of desferrioxamine with N,N'-ethylene-bis[2-hydroxy-5-carboxyphenylglycine].
Intravenous injection of the gallium chelating agents, N,N'-ethylene bis[2-hydroxy-5-carboxyphenyl-glycine], (COOH-EHPG), or desferrioxamine (DFO) after gallium-67 (67Ga) injection, improved tumour/non-tumour tissue uptake ratios in mice bearing the EMT-6 sarcoma. Six hours post injection of gallium and 2 h post chelator, COOH-EHPG enhanced the tumour/blood ratios by an order of magnitude compared to untreated controls, whereas DFO increased the ratios three-fold. Twenty two hours post gallium and 2 h post chelator, the increases in ratios compared to controls were seven-fold for COOH-EHPG and two-fold for DFO. The study thus demonstrated the superior ability of COOH-EHPG for the enhancement of 67Ga tumour/blood ratios compared with DFO.
Hunt
F C
FC
Australian Nuclear Science and Technology Organisation, Lucas Heights Research Laboratories, Menai, NSW.
D000818:Animals; D002614:Chelating Agents / Q000494:pharmacology*; D002951:Citrates / Q000378:metabolism; D019343:Citric Acid; D003676:Deferoxamine / Q000494:pharmacology*; D005029:Ethylenediamines / Q000494:pharmacology*; D007945:Leukemia, Lymphoid / Q000000981:diagnostic imaging*; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging*; D051379:Mice; D008807:Mice, Inbred BALB C; D011877:Radionuclide Imaging; D014018:Tissue Distribution
D002614:Chelating Agents; D002951:Citrates; D005029:Ethylenediamines; C011813:ethylenediamine-N,N'-bis(2-hydroxyphenylacetic acid); D019343:Citric Acid; D003676:Deferoxamine